Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis
Publication
, Conference
Aapro, M; Schwenkglenks, M; Lyman, G; Lopez-Pousa, A; Bacon, P; Lawrinson, S; Von Minckwitz, G
Published in: European Journal of Cancer Supplements
April 2008
Duke Scholars
Published In
European Journal of Cancer Supplements
DOI
ISSN
1359-6349
Publication Date
April 2008
Volume
6
Issue
7
Start / End Page
195 / 196
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Aapro, M., Schwenkglenks, M., Lyman, G., Lopez-Pousa, A., Bacon, P., Lawrinson, S., & Von Minckwitz, G. (2008). Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis. In European Journal of Cancer Supplements (Vol. 6, pp. 195–196). Elsevier BV. https://doi.org/10.1016/s1359-6349(08)70805-x
Aapro, M., M. Schwenkglenks, G. Lyman, A. Lopez-Pousa, P. Bacon, S. Lawrinson, and G. Von Minckwitz. “Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis.” In European Journal of Cancer Supplements, 6:195–96. Elsevier BV, 2008. https://doi.org/10.1016/s1359-6349(08)70805-x.
Aapro M, Schwenkglenks M, Lyman G, Lopez-Pousa A, Bacon P, Lawrinson S, et al. Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis. In: European Journal of Cancer Supplements. Elsevier BV; 2008. p. 195–6.
Aapro, M., et al. “Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis.” European Journal of Cancer Supplements, vol. 6, no. 7, Elsevier BV, 2008, pp. 195–96. Crossref, doi:10.1016/s1359-6349(08)70805-x.
Aapro M, Schwenkglenks M, Lyman G, Lopez-Pousa A, Bacon P, Lawrinson S, Von Minckwitz G. Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis. European Journal of Cancer Supplements. Elsevier BV; 2008. p. 195–196.
Published In
European Journal of Cancer Supplements
DOI
ISSN
1359-6349
Publication Date
April 2008
Volume
6
Issue
7
Start / End Page
195 / 196
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis